ロード中...
Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
Introduction: A proof-of-concept study was designed to evaluate the antiviral efficacy, safety and tolerability of a two-drug regimen with dolutegravir 50 mg once daily (QD) plus lamivudine 300 mg once daily as initial highly active antiretroviral therapy (HAART) among antiretroviral (ARV)-naive pat...
保存先:
| 出版年: | J Int AIDS Soc |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5515053/ https://ncbi.nlm.nih.gov/pubmed/28537061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.20.01.21678 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|